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ABSTRACT		A	simple,	Accurate	and	precise	method	was	developed	for	the	simultaneous	estimation	of	the	Grazoprevir	and	Elbasvir	 in	Tablet	dosage	 form.	Chromatogram	was	run	 through	Kromosil	C18	(250	x	4.6	mm),	5m.	Mobile	phase	containing	Buffer:	Acetonitrile	taken	in	the	ratio	45:55	was	pumped	through	column	at	a	flow	rate	of	1	ml/min.	Buffer	used	in	this	method	was	Di	Potassium	Hydrogen	ortho	Phosphate.	Temperature	was	maintained	at	30°C.	Optimized	wavelength	selected	was	215	nm.	Retention	time	of	Elbasvir	and	Grazo-previr	and	were	found	to	be	2.503	min	and	3.004.	%RSD	of	the	Elbasvir	and	Grazoprevir	were	and	found	to	be	0.3	and	0.4	respectively.	%Recovery	was	obtained	as	98.17%	and	99.83%	for	Grazoprevir	and	Elbasvir	respectively.	LOD,	LOQ	values	obtained	from	regression	equations	of	Grazoprevir	and	Elbasvir	were	0.24,	0.73	and	0.06,	0.19	respectively.	Retention	times	were	decreased	and	run	time	was	decreased,	so	the	method	developed	was	simple	and	economical	that	can	be	adopted	in	regular	Quality	control	test	in	Industries.	
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INTRODUCTION	Development	 of	 simple	 and	 reproducible	 analytical	methods	 for	estimation	of	multicomponent	drugs	 is	
very	important	part	of	quality	control	and	for	social	awareness	which	is	established	in	present	work	[1]	Grazoprevir[3]	 is	 a	 second	 generation	 protease	inhibitor	 approved	 for	 the	 treatment	 of	 hepatitis	 C	virus	(HCV)	in	combination	with	Elbasvir	as	the	fixed-dose	combination	product	Zepatier	(FDA).	Use	of	this	medication	 is	 indicated,	with	 our	without	 ribavirin,	for	the	treatment	of	adults	with	HCV	genotypes	is	an	integral	part	of	viral	replication	as	it	is	responsible	for	cleaving	 the	 long	 polypeptide	 produced	 following	translation	 of	 the	 viral	 genome[2].	 By	 inhibiting	protease	activity,	Grazoprevir	prevents	the	formation	of	structural	and	non-structural	proteins	required	for	replication	and	assembly.	Elbasvir[4]	 is	 an	 inhibitor	 of	 the	 Hepatitis	 C	 Virus	(HCV)	 Non-Structural	 protein	 5A	 (NS5A).	 Although	NS5A	has	no	known	enzymatic	function,	it	has	been	shown	to	have	multiple	functions	at	various	stages	of	the	 life	 cycle,	 including	 viral	 replication,	 virion	assembly,	 and	 use	 within	 multi-protein	 binding	complexes.	Combining	Elbasvir	with	other	drugs	that	target	other	points	of	the	viral	life	cycle	and	with	non-overlapping	 resistance	 profiles	 results	 in	 increased	potency	and	an	improved	barrier	to	resistance[2].	
MATERIALS	AND	METHODS		
Chemical	 and	 Reagents:	Grazoprevir	 and	 Elbasvir	were	kindly	gifted	by	Nutech	Labs	Pvt	Ltd,	Hyderabad	
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certified	 to	 contain	 99.9%	 and	 99.6%	 purity	respectively.	 The	 drugs	 were	 used	 without	 further	purification.	All	the	solvents	used	in	analysis	were	of	HPLC	grade.	
HPLC	method	
Instrument:	LC	system	used	consists	of	Waters	HPLC	having	 Empower	 Software	 with	 2695	 separation	module	 having	 PDA	 detector	 with	 universal	 loop	injector	of	injection	capacity	20	μL.	The	column	used	was	 Kromosil	 C18	 Column,	 5μ	 (250×	 4.6	 mm)	 at	ambient	temperature.	Different	mobile	phases	were	tested	 in	 order	 to	 find	 the	 best	 conditions,	 for	separating	both	the	drugs	simultaneously.	
Optimised	Chromatographic	conditions	The	 mobile	 phase	 having	 DiPotassium	 hydrogen	phosphate	 buffer	 (pH	 4.0)	 and	 Acetonitrile	 in	 the	ratio	of	45:55	v/v	was	selected	because	it	was	found	that	 it	 ideally	resolve	the	peaks	with	retention	time	(RT)	 3.004	min	 and	2.503	min	 for	Grazoprevir	 and	Elbasvir	 respectively.	 Wavelength	 was	 selected	 by	scanning	 all	 standard	 drugs	 over	 a	 wide	 range	 of	wavelength	200nm	to	350nm.	Both	the	components	showed	reasonably	good	response	at	215	nm.	
Preparation	of	Phosphate	Buffer:	Accurately	weigh	1.732g	 of	 DiPotassium	 hydrogen	 ortho	 phosphate	was	taken	in	a	500ml	volumetric	flask,	dissolved	and	diluted	 to	 500ml	with	HPLC	water	 and	 the	 volume	was	adjusted	to	pH	4.0	with	Ortho	Phosphoric	Acid.		
Preparation	of	Mobile	Phase:	Accurately	measured	450	ml	(45%)	of	above	buffer	and	550	ml	of	Acetoni-trile	(HPLC	Grade)	(55%)	were	mixed	and	degassed	in	an	ultrasonic	water	bath	for	10	minutes	and	then	filtered	through	0.45	μ	filter	under	vacuum	filtration.		
Diluent	Preparation:	Water	and	Acetonitrile	in	the	ratio	50:50	
Standard	Solution	Preparation		Accurately	Weighed	and	transferred	10mg	of	Grazo-previr	and	5mg	of	Elbasvir	working	Standards	into	a	10ml	clean	dry	volumetric	flask,	add	3/4th	volume	of	diluent,	Sonicated	for	5	minutes	and	make	up	to	the	final	volume	with	diluents.	1ml	from	the	above	stock	solution	was	taken	into	a	10ml	volumetric	flask	and	made	up	to	10ml.			
Procedure:	Inject	20	μL	of	the	standard,	sample	into	the	chromatographic	system	and	measure	the	areas	for	Grazoprevir	and	Elbasvir	peaks	and	calculate	the	%Assay	by	using	the	formulae.	
Pharmaceutical	Sample	Solution	(from	Formula-
tion)		
Sample	Solution	Preparation:	1tablet	was	weighed,	powdered	 and	 then	 was	 transferred	 into	 a	 100mL	
volumetric	 flask,	 50mL	 of	 diluent	 added	 and	 Soni-cated	 for	25	min,	 further	 the	volume	made	up	with	diluent	and	 filtered.	From	the	 filtered	solution	1	ml	was	 pipeted	 out	 into	 a	 10	ml	 volumetric	 flask	 and	made	up	to	10ml	with	diluent.			
RESULTS	AND	DISCUSSION		
Preparation	 of	 Calibration	 Curves	 by	HPLC:	 In	 a	series	of	10	ml	volumetric	 flask	several	dilutions	of	Grazoprevir	 (25-150	 μg/ml)	 and	 Elbasvir	 (12.5-75	μg/ml)	were	prepared	using	mobile	phase	as	solvent.	Each	solution	was	injected	into	HPLC	system	and	the	chromatograms	 were	 recorded.	 The	 peak	 areas	 of	both	drugs	were	 calculated	 and	 the	 respective	 cali-bration	curves	were	plotted	against	ratio	of	area	un-der	curve	and	concentration	of	drug.		The	equations	of	the	regression	lines	obtained	are		For	Grazoprevir:	R²	=	0.999	for	Elbasvir:	R²	=	0.999	
HPLC	Method	Validation:	As	per	the	ICH	guidelines,	the	method	validation	parameters	checked	were	lin-earity,	accuracy,	Specificity,	precision,	limit	of	detec-tion,	limit	of	quantitation.		
Linearity	Linearity	solutions	are	prepared	such	that	0.25,	0.5,	0.75,	1,	1.25,	1.5ml	from	the	Stock	solutions	of	Grazo-previr	and	Elbasvir	are	 taken	 in	 to	6	different	volu-metric	flasks	and	diluted	to	10ml	with	diluents	to	get	25ppm,	50ppm,	75ppm,	100ppm,	125ppm,	150ppm	of	 Grazoprevir,	 and	 12.5ppm,	 25ppm,	 37.5ppm,	50ppm,	62.5ppm,	75ppm	of	Elbasvir.		
Precision	Precision	 of	 the	 analytical	 method	 was	 studied	 by	analysis	of	multiple	sampling	of	homogeneous	sam-ple.	Precision	was	demonstrated	by	repeatability	and	intermediate	 precision	measurements	 of	 peak	 area	and	peak	symmetry	parameters	of	HPLC	method	for	each	 title	 ingredients.	The	 repeatability	 (within-day	in	triplicates)	and	intermediate	precision	(for	2	days)	were	carried	out	at	five	concentration	levels	for	each	compound.	Triplicate	 injections	were	made	and	 the		obtained	results	within	and	between	the	days	of	trials	were	in	acceptable	range.	The	value	of	%RSD	for	Gra-zoprevir	and	Elbasvir	were	found	to	be	less	than	2	in-dicates	that	the	developed	method	is	precise.	
Accuracy	Accuracy	of	an	analytical	method	is	the	closeness	of	test	results	obtained	by	that	method	to	the	true	value.	The	accuracy	of	 an	analytical	method	 should	be	es-tablished	across	its	linearity	range.	Accuracy	was	per-formed	 in	 three	different	 levels,	 each	 level	 in	 tripli-cate	for	Grazoprevir	and	Elbasvir	using	standards	at	50%,	100%	and	150%.	Each	sample	was	analysed	in		
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Figure	1:	Overlain	UV	Spectrum	of	Grazoprevir	and	Elbasvir	
	
Figure	2:	Chromatogram	of	Standard	solution	1.	Elb	(Rt	2.503),	2.Gra	(Rt	3.004)	at	215	nm	
	
Figure	3:	Chromatogram	of	Sample	solution	
	
Figure	4:	Linerity	curve	of	Grazoprevir
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Figure	5:	Linearity	curve	of	Elbasvir	
Table	1:	Precision	Results	for	Grazoprevir	and	Elbasvir	
S. No Area of  Grazoprevir Area of Elbasvir 
1. 2492363	 1192724	
2. 2497047	 1187341	
3. 2496265	 1181393	
4. 2490241	 1192596	
5. 2491112	 1189902	
6. 2511739	 1195604	
Mean 2496461	 1189927	
S.D 7973.6	 5033.7	
%RSD 0.3	 0.4	
Table	2:	The	accuracy	results	for	Grazoprevir	
%  Level Amount Spiked (µg/mL) 
Amount recovered 
(µg/mL) % Recovery Mean % Recovery 
50% 
50 49.27554 98.55 
99.17% 
50 49.36205 98.72 
50 50.16528 100.33 
100% 
100 99.54017 99.54 
100 100.117 100.12 
100 100.5057 100.51 
150% 
150 147.3853 98.26 
150 147.3525 98.24 
150 147.3391 98.23 
Table	3:	The	accuracy	results	for	Elbasvir	
%  Level Amount Spiked (µg/mL) 
Amount recovered 
(µg/mL) % Recovery Mean % Recovery 
50% 
25 24.7406 98.96 
99.83% 
25 25.17932 100.72 
25 25.16172 100.65 
100% 
50 50.38295 100.77 
50 50.3068 100.61 
50 50.3577 100.72 
150% 
75 74.36386 99.15 
75 73.69611 98.26 
75 73.9683 98.62 
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Table	4:	LOD	and	LOQ	
Drug LOD LOQ 
Grazoprevir 0.24 0.73 
Elbasvir 0.06 0.19 
	
	
Figure	6:	Specifity	of	Blank	Chromatogram	
	
Figure	7:	Specifity	of	Drug	Chromatogram	
Table	5:	Degradation	Data	of	Grazoprevir	
S.NO Degradation Condition % Drug Degraded Purity Angle Purity Threshold 
1 Acid 4.54 0.663 0.795 
2 Alkali 2.75 0.807 0.988 
3 Oxidation 1.70 0.663 0.895 
4 Thermal 0.73 0.807 0.988 
5 UV 0.90 0.746 0.955 
6 Water 0.73 0.601 0.860 
Table	6:	Degradation	Data	of	Elbasvir	
S.NO Degradation Condition % Drug Degraded Purity Angle Purity Threshold 
1 Acid 4.80	 1.123	 1.315	
2 Alkali 2.48	 0.964	 1.319	
3 Oxidation 1.57	 1.123	 1.315	
4 Thermal 0.56	 0.964	 1.319	
5 UV 0.56	 0.984	 1.314	
6 Water 0.53	 0.964	 1.319	
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triplicate	 for	 each	 level.	 The	mean	 recoveries	were	found	in	the	range	of	98	–	102%,	by	which	we	can	say	the	method	was	accurate.	
Limit	 of	 Detection	 (LOD)	 and	 Limit	 of	 Quantita-
tion	(LOQ)	It	 is	 calculated	 according	 to	 ICH	 recommendations	where	 the	 approach	 is	 based	on	 the	 signal-to-noise	ratio.	 Chromatogram	 signals	 obtained	 with	 known	low	concentrations	of	analytes	were	compared	with	the	signals	of	blank	samples.	A	 signal-to-noise	 ratio	3:1	and	10:1	was	considered	for	calculating	LOD	and	LOQ	respectively.	
Specifity	Volume	of	20	μL	of	working	placebo	sample	solution	was	injected	into	the	chromatograph	and	the	chroma-togram	was	recorded	and	presented	below.	
Degradation	studies	
Oxidation:	To	2	ml	of	stock	solution	of	Grazoprevir	and	Elbasvir,	2	ml	of	20%	hydrogen	peroxide	(H2O2)	was	added	separately.	The	solutions	were	kept	for	30	min	at	600c.	For	HPLC	study,	 the	resultant	solution	was	 diluted	 to	 obtain	 100µg/ml&50µg/ml	 solution	and	10	µl	were	injected	into	the	system	and	the	chro-matograms	were	 recorded	 to	 assess	 the	 stability	 of	sample.	
Acid	Degradation	Studies:	To	2	ml	of	stock	s	solu-tion	Grazoprevir	and	Elbasvir,	2ml	of	2N	Hydrochlo-ric	acid	was	added	and	refluxed	for	30mins	at	600c	.The	 resultant	 solution	 was	 diluted	 to	 obtain	100µg/ml&50µg/ml	 solution	 and	 10	 µl	 solutions	were	 injected	 into	 the	 system	 and	 the	 chromato-grams	were	recorded	to	assess	the	stability	of	sample.	
Alkali	Degradation	Studies:	To	2	ml	of	stock	solu-tion	Grazoprevir	and	Elbasvir,	2	ml	of	2N	sodium	hy-droxide	was	added	and	refluxed	for	30mins	at	600c.	The	 resultant	 solution	 was	 diluted	 to	 obtain	100µg/ml&50µg/ml	solution	and	10	µl	were	injected	into	 the	 system	 and	 the	 chromatograms	 were	 rec-orded	to	assess	the	stability	of	sample.	
Dry	Heat	Degradation	Studies:	The	standard	drug	solution	was	placed	in	oven	at	105°C	for	6	h	to	study	dry	heat	degradation.	For	HPLC	study,	the	resultant	solution	was	diluted	to	100µg/ml&50µg/ml	solution	and10µl	were	injected	into	the	system	and	the	chro-matograms	were	 recorded	 to	 assess	 the	 stability	 of	the	sample.	
Photo	Stability	studies:	The	photochemical	stability	of	 the	 drug	 was	 also	 studied	 by	 exposing	 the	1000µg/ml&	 &500µg/ml	 solution	 to	 UV	 Light	 by	keeping	the	beaker	in	UV	Chamber	for	1days	or	200	Watt	hours/m2	in	photo	stability	chamber.	For	HPLC	study,	 the	 resultant	 solution	 was	 diluted	 to	 obtain	100µg/ml	50µg/ml	solutions	and	10	µl	were	injected	
into	 the	 system	 and	 the	 chromatograms	 were	 rec-orded	to	assess	the	stability	of	sample.	
Neutral	Degradation	Studies:	Stress	 testing	under	the	neutral	 conditions	was	 studied	by	 refluxing	 the	drug	 in	water	 for	 1	 hour	 at	 60°C	 temperature.	 For	HPLC	 study,	 the	 resultant	 solution	 was	 diluted	 to	100µg/ml&	 &50µg/ml	 solution	 and	 10	 µl	 were	 in-jected	into	the	system	and	chromatograms	were	rec-orded	to	access	the	stability	of	sample.	
CONCLUSION	The	methods	described	for	simultaneous	estimation	of	Grazoprevir	and	Elbasvir	are	 found	 to	be	simple,	sensitive,	 accurate,	 precise,	 rapid	 and	 economical.	Hence	 method	 could	 be	 successfully	 employed	 for	routine	analysis	of	Grazoprevir	and	Elbasvir	in	their	combined	dosage	form.	
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